FibroGen (FGEN) Projected to Post Quarterly Earnings on Monday

FibroGen (NASDAQ:FGEN) will likely be issuing its Q3 2025 results after the market closes on Monday, November 10th. Analysts expect the company to announce earnings of ($4.01) per share and revenue of $1.64 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Monday, November 10, 2025 at 5:00 PM ET.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings data on Monday, August 11th. The biopharmaceutical company reported ($3.38) earnings per share for the quarter, missing the consensus estimate of ($2.25) by ($1.13). The company had revenue of $1.30 million during the quarter, compared to the consensus estimate of $2.88 million. On average, analysts expect FibroGen to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

FibroGen Stock Up 0.3%

FGEN stock opened at $11.03 on Friday. FibroGen has a 52-week low of $4.50 and a 52-week high of $21.94. The stock has a market cap of $44.61 million, a price-to-earnings ratio of -29.03 and a beta of 0.75. The business has a fifty day moving average of $11.42 and a two-hundred day moving average of $9.00.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Wall Street Zen raised FibroGen from a “sell” rating to a “hold” rating in a research report on Saturday, September 13th. HC Wainwright reissued a “buy” rating and issued a $43.00 price target on shares of FibroGen in a research note on Wednesday, September 24th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of FibroGen in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, FibroGen presently has a consensus rating of “Hold” and an average target price of $43.00.

Institutional Inflows and Outflows

An institutional investor recently raised its position in FibroGen stock. Vanguard Group Inc. increased its holdings in shares of FibroGen, Inc (NASDAQ:FGEN) by 3.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 184,244 shares of the biopharmaceutical company’s stock after buying an additional 6,204 shares during the period. Vanguard Group Inc. owned about 4.56% of FibroGen worth $2,257,000 at the end of the most recent quarter. Institutional investors own 72.71% of the company’s stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.